ArticleNature communications2019
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 94 citations in OpenAlex.
- A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial.Nature medicine · 2026Trial
- Regulation of Tph cell differentiation via farnesoid X receptor of dendritic cells in inflammatory bowel disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Machine learning-based identification of a metabolic cell death gene signature for assessing disease activity and immunological landscape in inflammatory bowel disease.Scientific reports · 2026Article
- Real-world effectiveness and safety of carotegrast methyl in patients with ulcerative colitis: a multicenter retrospective cohort study.Intestinal research · 2026Article
- Single-cell Unperturbed Activation Profiling by mass cytometry capturesFrontiers in immunology · 2026Article
- Ulcerative colitis, but not Crohn's disease, displays demographically and clinically driven mucosal immune heterogeneity: implications for patient stratification.Frontiers in immunology · 2026Article
- Evaluating objective nutritional biomarkers for the prediction of sarcopenia in Crohn's disease: development and internal validation of a clinical nomogram.Frontiers in nutrition · 2026Article
- Systems Human Immunology and AI: Immune Setpoint and Immune Health.Annual review of immunology · 2025Review
- Recent Evidence of the Role of CD4JMA journal · 2025Review
- Next-generation non-animal models for inflammatory bowel disease:NAM journal · 2025Review
- Biomarker discovery for non-invasive diagnosis of inflammatory bowel disease using blood transcriptomics.Frontiers in immunology · 2025Article
- Optimal transport reveals immune perturbation and fingerprints over time in COVID-19 vaccination.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel disease.Frontiers in immunology · 2025Review
- Organosilicone double-long-chain diquaternary ammonium salt acts as a biofilm scavenger to ameliorate colitis induced by dextran sulfate sodium salt.Frontiers in immunology · 2025Article
- Exploring Immune Cell Infiltration and Small Molecule Compounds for Ulcerative Colitis Treatment.Genes · 2024Article
- CXCL13: a common target for immune-mediated inflammatory diseases.Clinical and experimental medicine · 2024Review
- Automated spatial omics landscape analysis approach reveals novel tissue architectures in ulcerative colitis.Scientific reports · 2024Article
- In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations.Cancer science · 2024Article
- Automated Spatial Omics Landscape Analysis Approach Reveals Novel Tissue Architectures in Ulcerative Colitis.Research square · 2024Article
- Surface protein and functional analyses identify CD4+CD39+ TCR αβ+ and activated TCR Vδ1+ cells with distinct pro-inflammatory functions in Crohn's disease lesions.Clinical and experimental immunology · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis. Each disease is characterized by a diverse set of potential manifestations, which determine patients' disease phenotype. Current understanding of phenotype determinants is limited, despite increasing prevalence and healthcare costs. Diagnosis and monitoring of disease requires invasive procedures, such as endoscopy and tissue biopsy. Here we report signatures of heterogeneity between disease diagnoses and phenotypes. Using mass cytometry, we analyze leukocyte subsets, characterize their function(s), and examine gut-homing molecule expression in blood and intestinal tissue from healthy and/or IBD subjects. Some signatures persist in IBD despite remission, and many signatures are highly represented by leukocytes that express gut trafficking molecules. Moreover, distinct systemic and local immune signatures suggest patterns of cell localization in disease. Our findings highlight the importance of gut tropic leukocytes in circulation and reveal that blood-based immune signatures differentiate clinically relevant subsets of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.